Eton Pharmaceuticals, Inc. announced that it has entered into agreements to issue and sell 1,287,500 shares of common stock at a price of $3.50 per share for gross proceeds of $4,506,250 and to issue pre-funded warrants to purchase an aggregate of 2,462,500 shares of common stock at a price of $3.50 per share for gross proceeds of $8,618,750 for the aggregate gross proceeds of $13,125,000 on April 15, 2024. The Company also entered into an agreement to expand its existing credit facility by $21.9 million to $27.0 million and in connection therewith agreed to issue a warrant to the lender for up to 358,976 shares of common stock at a price of $3.66 per share
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.34 USD | -2.77% | -9.70% | -23.52% |
May. 09 | Transcript : Eton Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q1 Revenue $8M, vs. Street Est of $8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.52% | 88.24M | |
+8.05% | 72.94B | |
+12.64% | 9.06B | |
-10.56% | 5.07B | |
+58.79% | 4.78B | |
+4.07% | 3.9B | |
-16.90% | 2.56B | |
+21.35% | 2.42B | |
-26.13% | 2.39B | |
+19.31% | 2.18B |
- Stock Market
- Equities
- ETON Stock
- News Eton Pharmaceuticals, Inc.
- Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding